Menu
Recruiting NCT05874206

CRATOS - Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions

No phase Interventional Aortic Dissection Type B Intramural Hematoma Penetrating Aortic Ulcer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cratos™ Stent Graft.
Who it may be relevant to
Registry conditions: Aortic Dissection Type B, Intramural Hematoma, Penetrating Aortic Ulcer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Switzerland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions

Overview

The goal of this prospective, interventional, multicentre, single-arm performance objective study is to evaluate efficacy and safety of Cratos™ Branch Stent Graft System in treatment of lesions (dissection, IMH and PAU in descending aorta. The main question\[s\] it aims to answer are: * 30-day all-cause Mortality rate * Composite of the following events from the time of enrolment through 12-month: * Device Technical Success * Absence of: Aortic rupture, Lesion-related mortality, Disabling Stroke, Permanent paraplegia, Permanent paraparesis, New onset renal failure requiring permanent dialysis, Additional unanticipated post-procedural surgical or interventional procedure related to the device, procedure, or withdrawal of the device system Participants will come for hospital office visits 1, 6, 12, 24-, 36-, 48- and 60-months post-procedure for the following, but not limited to assessments: * Physical examination * Modified Rankin scale * Tarlov scoring scale * CTA

Interventions

  • Device Cratos™ Stent Graft
    Cratos™ Stent Graft TEVAR procedure for the treatment of aortic lesions.

Primary outcome measures

  • Mortality [Time frame: 30-day]

Eligibility criteria

Inclusion criteria

  • Presence of thoracic aortic pathology (Dissection, including IMH and ULP; and PAU) deemed to warrant surgical repair which requires proximal graft placement in Zone 2
  • Age ≥18 years at time of informed consent signature
  • Informed Consent Form (ICF) is signed by Subject or legal representative
  • Must have appropriate proximal aortic landing zone, defined as:
  • Landing zone inner diameters between 23-41 mm
  • The length of landing zone ≥15mm
  • Landing without heavily calcified or heavily thrombosed
  • Dissection Patients: Primary entry tear must be distal to LSA, and proximal extent of the proximal landing zone must not be dissected.
  • For patients with prior replacement of the ascending aorta and/or aortic arch by a surgical graft, there must be at least 2 cm of landing zone proximal to the most distal anastomosis site.
  • Must have appropriate LSA landing zone, defined as:
  • Inner diameters of LSA 5-14 mm
  • Minimum length of Left subclavian artery is 25 mm
  • Target branch vessel landing zone must be in native aorta that cannot be severely tortuous , aneurysmal, dissected, heavily calcified, or heavily thrombosed.
  • Must have appropriate distal aortic landing zone, defined as:
  • Aortic inner diameters between 18-44 mm
  • Landing zone cannot be heavily calcified, or heavily thrombosed.
  • For isolated PAU, outer curvature length must be ≥ 2cm proximal to the celiac artery
  • Landing zone in native aorta

Exclusion criteria

  • Concomitant disease of the ascending aorta or aneurysm of the abdominal aorta requiring repair
  • Previous endovascular repair of the ascending aorta
  • Infected aorta, active systemic infection
  • Surgery within 30 days prior to enrolment with the exception of placement of vascular conduit for access .
  • Life expectancy <1 years
  • Myocardial infarction within 6 weeks prior to treatment
  • Stroke within 6 weeks prior to treatment.
  • Pregnant or breastfeeding female
  • Patient has an active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication) that may place the patient at increased risk of endovascular infection.
  • Degenerative connective tissue disease, e.g., Marfan's or Ehlers-Danlos Syndrome
  • Participation in another drug or medical device study within one year of study enrolment
  • Known history of drug abuse within one year of treatment
  • Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access
  • Planned coverage of celiac artery
  • Allergic to contrast agents, anaesthetics and delivery materials
  • Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin
  • Patient with a history of a hypercoagulability disorder and/or is currently in a hypercoagulability state
  • Persistent refractory shock (systolic blood pressure <90 mm Hg)
  • Renal failure defined as patients with an estimated Glomerular Filtration Rate (eGFR) <30 (ml/min/1.73 m2) or currently requiring dialysis
  • Contraindications to antiplatelet drugs and anticoagulants
  • Investigator judged that not suitable for interventional treatment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Switzerland · 1 center
  • University Hospital Zurich — Zurich

Identifiers

NCT: NCT05874206 · ENDO_E23-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗